Meta-analysis of COVID-19 prevalence during preoperative COVID-19 screening in asymptomatic patients

Ellen de Bock,1 Mando D Filipe,1 Roger K J Simmermacher,2 A Christiaan Kroese,3 Menno R Vriens,1 Milan C Richir1

ABSTRACT

Objectives Patients with COVID-19 may be asymptomatic and are able to transmit COVID-19 during a surgical procedure, resulting in increased pressure on healthcare and reduced control of COVID-19 spread. There remains uncertainty about the implementation of preoperative screening for COVID-19 in asymptomatic surgical patients. Therefore, this study aims to determine the prevalence of preoperative COVID-19, confirmed by reverse transcription PCR (RT-PCR), in asymptomatic patients.

Design Systematic review and meta-analysis.

Data sources Pubmed and Embase databases were searched through 20 February 2022.

Eligibility criteria All COVID-19 articles including preoperative asymptomatic patients were included.

Data extraction and synthesis Two independent reviewers extracted data and assessed risk of bias. Meta-analysis was performed to determine the prevalence of COVID-19 with 95% CI. Moreover, estimated positive predictive value (PPV), negative predictive value, false-positives (FP) and false-negatives were calculated for preoperative asymptomatic patients.

Results Twenty-seven studies containing 27,256 asymptomatic preoperative screened patients were included, of which 431 were positive for COVID-19 by RT-PCR test. In addition, the meta-analysis revealed a pooled COVID-19 prevalence of 0.76% (95% CI 0.36% to 1.59%). The calculated PPV for this prevalence is 40.8%.

Conclusions The pooled COVID-19 prevalence in asymptomatic patients tested preoperatively was 0.76%, with low corresponding PPV. Consequently, nearly three-quarters of postponed surgical procedures in asymptomatic preoperative patients may be FP. In the event of similar pandemics, modification of preoperative mandatory RT-PCR COVID-19 testing in asymptomatic patients may be considered.

INTRODUCTION

Since the declared COVID-19 pandemic, many countries have experienced peaks in the number of infected patients.1 As a result of the confirmed COVID-19 cases, restrictive measures were implemented, including postponing (elective) surgical procedures.2–7 Performing surgical procedures was accompanied by alterations in clinical practice, including introducing preoperative guidelines for COVID-19 screening to minimise the risk of spreading COVID-19.8–11 While these preoperative guidelines differed in the preferred type of COVID-19 test, they all recommended testing every (surgically admitted) patient.8–11 As a result, many patients without accompanying COVID-19 symptoms are tested preoperatively.

The majority of the patients with confirmed COVID-19 experience mild influenza-like symptoms, including fever, cough, dyspnoea, sputum secretions, fatigue and malaise.12 13 However, a significant proportion (15%–25%) of the COVID-19 infected patients may be asymptomatic.14 15 Since tracheal intubation is an aerosol-generating procedure and COVID-19 has the ability to remain viable and infectious on certain surfaces during a surgical procedure, there may be an increased risk of viral transmission during surgical procedures.16–18 Consequently, these infected asymptomatic patients may be able to spread the virus to healthcare personnel and other hospitalised patients.19–25 Nevertheless, mandatory COVID-19 screening before all surgical procedures requires testing equipment and is time-consuming, leading to additional pressure on hospital staff and overall healthcare and increased costs.24 25 Ambiguity remains about the necessity and implementation of the

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Inclusion of all studies on reverse transcription PCR (RT-PCR) COVID-19 asymptomatic patients tested preoperatively during the COVID-19 pandemic.

⇒ Analyses of COVID-19 prevalence of large population of patients without COVID-19-like symptoms.

⇒ Calculation of corresponding positive predictive value, negative predictive value, true positives and false positives for this prevalence.

⇒ True positives and false positives could not be determined in asymptomatic patients tested with RT-PCR only since studies excluded patients presenting with symptoms.

⇒ Analyses did not include other COVID-19 diagnostic tests besides RT-PCR.
testing guidelines for preoperative screening in asymptomatic surgical patients. Therefore, this systematic review and meta-analysis aims to determine the COVID-19 prevalence in asymptomatic patients tested preoperatively and determine the implications for clinical screening by calculating diagnostic, predictive values.

**MATERIALS AND METHODS**

**Search strategy**

This systematic review and meta-analysis was performed according to the guidelines’ requirements of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Checklist for meta-analysis. A systematic literature search was performed in the PubMed and Embase databases, including all articles published before 20 February 2022. Search strategy contained a combination of keywords (and their synonyms), including ‘screening,’ ‘preoperative,’ ‘SARS-CoV-2’. The complete search strategy is available in online supplemental table 1.

**Study selection**

After removing duplicates, two reviewers (EdB and MDF) independently screened articles for eligibility using title and abstract. The two authors discussed conflicting judgements until consensus was reached. All articles with asymptomatic patients requiring a surgical or interventional procedure with a high risk of generating COVID-19 aerosols were selected for full article review. In addition, articles from which absolute numbers of true positive (TP), false-positive (FP), true negative (TN) or false-negative (FN) could be derived were included. Subsequently, articles were required to perform COVID-19 screening through symptom screening and reference reverse transcriptase PCR (RT-PCR) test or COVID-19 screening by chest CT and reference RT-PCR test.

Studies were excluded from the systematic review for the following reasons: diagnostic testing in asymptomatic patients only; non-human biological sample usage; no English language article, case reports, case series, editorials, commentaries, short communications, letters, review articles, conference abstracts; no full text available. The reviewers (EdB and MDF) reviewed the retrieved full-text articles. Agreement for eligibility was obtained for all articles.

**Data extraction and definitions**

The following data were extracted from each eligible study: first author’s surname, publication year, study period, number of asymptomatic patients, type of surgical division, COVID-19 preoperative screening method, COVID-19 reference test, number of days symptom screening was performed before surgical procedure, number of TP, number of FP, number of TN, number of FN.

CT-scan positive for COVID-19 was defined as COVID-19 Reporting and Data System (CO-RADS) ≥4 or if scored as ‘typical COVID-19’ or ‘indeterminate’ according to the European Society of Radiology guidelines and the European Society of Thoracic Imaging. Symptom screening included but was not limited to dyspnoea, cough, fever or influenza-like symptoms. Surgical patients were determined ‘asymptomatic’ if none of the aforementioned symptoms were present. In addition, some studies evaluated high-risk exposures, travel outside the country, or recent contact with a COVID-19 confirmed individual. If studies implemented different preoperative screening protocols due to changes in national screening guidelines, only data from the relevant protocol was retrieved. Postoperative COVID-19 test results were not included in the analysis. The prevalence of positive COVID-19 patients was defined as the percentage of patients who tested positive for SARS-CoV-2 out of all asymptomatic patients tested preoperatively.

**Patient and public involvement**

We did not seek patient or public comment in designing the study.

**Bias assessment**

The risk of bias for each eligible study was independently evaluated by the reviewers (EdB and MDF) using the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) Tool. The tool consists of seven domains: confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes and selection of the reported result. Each domain was rated on three levels of bias: low risk, intermediate/unclear risk, or high risk of bias. The two authors discussed discordant judgements until consensus was reached. Full assessment criteria can be found in online supplemental figure 1.

**Statistical analysis**

Meta-analysis was performed using a random effects model to determine the prevalence with 95% CI of asymptomatic COVID-19 positive patients.

Calculation of the estimated positive predictive value (PPV) was established by the following mathematical formula:

\[
PPV = \frac{\text{sensitivity} \times \text{prevalence}}{[(\text{sensitivity} \times \text{prevalence})+(1-\text{specificity}) \times (1-\text{prevalence})]} 
\]

Calculation of the estimated NPV was established by the following mathematical formula:

\[
NPV = \frac{\text{specificity} \times (1-\text{prevalence})}{[(\text{specificity} \times (1-\text{prevalence}))+(1-\text{sensitivity}) \times \text{prevalence}]} 
\]

According to the WHO guideline, an acceptable sensitivity and specificity rate should be 90% and 99%, respectively, and were used to calculate PPV and NPV with the aforementioned formulas.

The effect of heterogeneity was quantified using $I^2$, if $I^2 >50\%$ or $p<0.05$, indicating significant heterogeneity across the studies. Meta-analysis was performed to compare the pooled prevalence of all included studies. The statistical analyses were carried out using the meta package in the R statistical software (V.4.0.2).
RESULTS
A total of 4166 articles were identified after duplicate removal. Of these, 4001 were excluded during the titles and abstracts screening, 165 articles were screened in full text (figure 1). Overall, 27 studies were included, 27256 asymptomatic patients were reviewed, of which 431 patients were tested COVID-19 positive by RT-PCR test. On average, symptom screening was performed less than 2 days before the surgical procedure.

Table 1 summarises the main characteristics of the included studies. All studies presented a COVID-19 screening method of either chest CT, symptom screening and RT-PCR or symptom screening and RT-PCR. Symptom screening with RT-PCR as the reference test...
## Table 1 Characteristics of the included studies on preoperative COVID-19 screening

| Author            | Country | Study period in 2020 | No of asymptomatic patients | Surgical discipline | Evaluated screening method | Reference screening method | TP | FP | TN | FN | Prevalence of COVID-19 (%) | No days symptom-screening before hospital admission |
|-------------------|---------|----------------------|-----------------------------|---------------------|---------------------------|----------------------------|----|----|----|----|---------------------------|------------------------------------------------------|
| Ap Dafydd et al  | UK      | April 1 - May 31     | 240                         | Oncology            | Symptom screening and chest CT | RT-PCR                    | 1  | 8  | 230| 1  | 0.83                      | NR                                                   |
| Bloom et al      | USA     | March 30 - April 12  | 84                          | Urgent, different disciplines | Symptom screening          | RT-PCR                    | 0  | 0  | 81 | 3  | 3.57                      | ≤2                                                  |
| Blumberg et al   | USA     | March 26 - June 13   | 1161                        | Orthopaedic         | Symptom screening          | RT-PCR                    | 0  | 0  | 1155| 6  | 0.52                      | ≤3                                                  |
| Castellvi et al  | Spain   | April 15 - May 4     | 171                         | Oncology            | Symptom screening          | RT-PCR                    | 0  | 0  | 171| 0  | 0.00                      | ≤2                                                  |
| Coatsworth et al | Australia | June 2 - July 17    | 3010                        | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 3010| 0  | 0.00                      | NR                                                  |
| Ferrari et al    | Italy   | March 16 - April 17  | 41                          | Oncology            | Symptom screening          | RT-PCR                    | 0  | 0  | 41 | 0  | 0.00                      | ≤7                                                  |
| Gruskay et al    | USA     | April 5 - April 24   | 81                          | Orthopaedic         | Symptom screening          | RT-PCR                    | 0  | 0  | 74 | 7  | 8.64                      | NR                                                  |
| Guerlain et al   | France  | March 25th and May 12th | 477                   | Orthopaedic         | Symptom screening and chest CT | RT-PCR                    | NR | NR | 459| 18 | 3.77                      | 0                                                   |
| Gümüs et al      | Turkey  | April 20 - May 31    | 218                         | Different divisions  | Symptom screening and chest CT | RT-PCR                    | 1  | 2  | 203| 2  | 1.38                      | NR                                                  |
| Gupta et al      | India   | April 18 - May 28    | 764                         | Different divisions  | Symptom screening          | RT-PCR or True-NAT RT-PCR | 0  | 0  | 762| 2  | 0.26                      | 0                                                   |
| Hendrickson et al| USA     | April 7 - May 21     | 1997                        | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 1990| 7  | 0.35                      | 0                                                   |
| Kannan et al     | India   | July 16 - August 31  | 413                         | Retinal             | Symptom screening          | RT-PCR                    | 0  | 0  | 404| 9  | 2.18                      | 0                                                   |
| Kavanagh et al   | Ireland | March 1 - June 30    | 156                         | Otolaryngology       | Symptom screening          | RT-PCR                    | 0  | 0  | 156| 0  | 0.00                      | 0                                                   |
| Lopes et al      | Brazil  | May – October       | 1636                        | Oncology            | Symptom screening          | RT-PCR                    | 0  | 0  | 1534| 102| 6.23                      | five and 1                                           |
| Myles et al      | Australia | July 15-August 31   | 4965                        | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 4961| 4  | 0.08                      | five and 0                                           |
| Nekkanti et al   | India   | April 18 - June 20   | 262                         | Oncology            | Symptom screening          | RT-PCR                    | 0  | 0  | 241| 21| 8.02                      | ≤2                                                  |
| Patkar et al     | India   | April - September    | 2108                        | Oncology            | Symptom screening          | RT-PCR                    | 0  | 0  | 1908| 200| 9.49                      | ≤2                                                  |
| Puylaert et al   | The Netherlands | March 20 - April 24  | 1224                        | Different divisions  | Symptom screening and chest CT | RT-PCR                    | 4  | 4  | 1206| 10 | 1.14                      | 0                                                   |
| Railhan et al    | India   | April 19 - May 29    | 64                          | Cardiac             | Symptom screening          | RT-PCR                    | 0  | 0  | 63 | 1  | 1.56                      | 0                                                   |
| Singer et al     | USA     | April 7 - May 21     | 4743                        | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 4737| 6  | 0.13                      | ≤2                                                  |
| Singh et al      | India   | September - December | 218                         | Ophthalmology       | Symptom screening          | RT-PCR                    | 0  | 0  | 202| 16| 7.34                     | 0                                                   |
| Shah et al       | USA     | March 1 - April 30   | 625                         | Different divisions  | Symptom screening and chest CT | RT-PCR                    | 0  | 0  | 605| 1  | 0.16                      | ≤7                                                  |
| Tilmans et al    | France  | March 2 - April 10   | 30                          | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 30 | 0  | 0.00                      | 0                                                   |
| Urban et al      | USA     | March 23 - April 17  | 21                          | Otolaryngology       | Symptom screening          | RT-PCR                    | 0  | 0  | 20 | 1  | 4.76                      | ≤4                                                  |
| Owalinski et al  | Poland  | June – July         | 94                          | Different divisions  | Symptom screening          | RT-PCR                    | 0  | 0  | 94 | 0  | 0.00                      | NR                                                  |
| Zangrilli et al  | USA     | May 1 – July 21      | 2329                        | Orthopaedics        | Symptom screening          | RT-PCR                    | 0  | 0  | 2324| 5  | 0.21                      | NR                                                  |
| Zahra et al      | UK      | May 4 - June 15      | 124                         | Orthopaedic         | Symptom screening          | RT-PCR                    | 0  | 0  | 121| 3  | 2.42                      | ≤5                                                  |

FN, false-negative; FP, false-positive; NR, not reported; RT-PCR, real time reverse transcriptase PCR; TN, true negative; TP, true positive.
was performed in 22 studies.\textsuperscript{34-41, 43-50, 53-59} Symptom screening with chest CT and RT-PCR as the reference test was performed in five studies.\textsuperscript{32-33, 42, 44, 52} Most (63\%) included studies were published in 2020. In addition, eight (29.6\%) studies were published in 2021 and two (7.4\%) in 2022 (figure 2). Most studies (85.2\%) were conducted during the first wave of the COVID-19 pandemic (table 1).

**Prevalence of COVID-19 in asymptomatic preoperative patients**

The forest plot in figure 2 shows the pooled prevalence (\%) of asymptomatic COVID-19 positive patients requiring a surgical procedure using a random effects model. The overall percentage of our study population was 0.76\% (95\% CI 0.36\% to 1.59\%) (figure 2). Moreover, the prevalence of COVID-19 positive asymptomatic surgical patients ranged from 0.00\% to 9.49\%. In addition, heterogeneity between studies was high (I\(^2\)=94\%) (figure 2).

**PPV, NPV, FP and FN of varying COVID-19 prevalence rates**

Table 2 shows the calculated PPV, NPV, FP and FN corresponding with the varying COVID-19 prevalence rates in asymptomatic preoperative patients. Calculated PPV and NPV, taking into account the WHO guidelines for sensitivity (90\%) and specificity (99\%) with the aforementioned prevalence of 0.76\%, were 40.8\% and 99.9\%, respectively. In addition, estimated FP and FN rates, with the previously mentioned prevalence, were 992 and 76, respectively. The lowest and highest prevalence of COVID-19 positive preoperatively tested asymptomatic patients in the included studies were 0.00\% and 9.49\%, respectively. The corresponding PPV and NPV with a

### Table 2

| COVID-19 prevalence (%) | PPV (%) | NPV (%) | FP (N) | FN (N) |
|-------------------------|---------|---------|--------|--------|
| 10.00                   | 90.9    | 98.9    | 900    | 1000   |
| 9.49*                   | 90.4    | 99.0    | 905    | 949    |
| 5.00                    | 82.6    | 99.5    | 950    | 500    |
| 1.00                    | 47.6    | 99.9    | 990    | 100    |
| 0.76†                   | 40.8    | 99.9    | 992    | 76     |
| 0.00‡                   | 0       | 100     | 1000   | 0      |

*The highest COVID-19 prevalence in our study population in the included studies.
†COVID-19 positive prevalence on average of the 27 included studies in this meta-analysis.
‡The lowest COVID-19 prevalence in our study population in the included studies.
FN, false-negative; FP, false-positive; N, number; NPV, negative predictive value; PPV, positive predictive value; RT-PCR, real time reverse transcriptase PCR.
9.49% prevalence were 90.4% and 99%, respectively (table 2).

Risk of bias
All studies were classified as overall methodological sufficient quality according to ROBINS-I Tool. Risk assessment of all studies is further described in online supplemental figure 1.

DISCUSSION
This current meta-analysis analysed the COVID-19 prevalence in asymptomatic patients requiring a surgical procedure. In total, 431 asymptomatic preoperative patients were tested SARS-CoV-2 positive by RT-PCR reference test. In addition, the meta-analysis showed a pooled COVID-19 prevalence of 0.76% (95% CI 0.36% to 1.59%) in asymptomatic patients tested preoperatively. Subsequently, with this prevalence, the corresponding NPV and PPV were 99.9% and 40.8%, respectively, with 59.2% of possible FP test results.

During the pandemic, it remained essential to continue and resume surgical procedures. However, caution was advised as 25% of patients may be asymptomatic and are able to transmit SARS-CoV-2, with potentially even greater risk during surgical procedures, which may lead to additional healthcare pressure due to morbidity, increased mortality and decreased control over the SARS-CoV-2 spread. In order to effectively conduct COVID-19 preoperative screening in asymptomatic patients, diagnostic COVID-19 screening methods require specific characteristics, such as low FN rates. Therefore, evaluating sensitivity and NPV is essential to determine the utility of diagnostic methods for preoperative COVID-19 screening in asymptomatic patients. Furthermore, high PPV are essential to determine as well since it represents the potential for FP COVID-19 patients. In addition, rapid test execution and availability of test results are additional important screening features as pressure on healthcare remains high and surgical care may increase in the coming months.

The current meta-analysis showed an overall low pooled prevalence (0.76%, 95% CI 0.36% to 1.59%) of COVID-19 positive asymptomatic preoperative patients. Nevertheless, this indicates that symptom screening without additional RT-PCR testing may lead to viral transmission. This is in line with previous literature stating that symptom screening of surgical patients alone is not sufficient. However, a recent review showed that asymptomatic patients are 42% less likely to transmit COVID-19 compared with symptomatic patients. Due to the previously mentioned low COVID-19 prevalence in our study population, the estimated PPV was low as well (40.8%). As a result, almost 60% (59.2%; 992 patients) of COVID-19 RT-PCR positive asymptomatic preoperative patients may be FP. Consequently, the surgical procedures of these patients will be deferred even though they will not spread COVID-19. This (unnecessary) postponement of surgical care may result in clinical deterioration, thereby contributing to additional pressure on healthcare and increasing costs. In addition, the currently used RT-PCR test for preoperative screening is time-consuming, requires a laboratory and additional healthcare providers.

The pressure on healthcare will remain high since the number of surgical procedures to be performed may increase. Therefore, consideration may be given to reviewing the mandatory COVID-19 screening approach of RT-PCR in asymptomatic preoperative patients. Additionally, the current meta-analysis showed a maximum COVID-19 prevalence in preoperatively tested asymptomatic patients of 9.49% with a corresponding PPV of 90.4%. Hence, further research should determine which areas and affiliated hospitals require preoperative COVID-19 testing.

This meta-analysis has some limitations. First, since we used symptom screening in asymptomatic patients as an index test for preoperative COVID-19 screening, TP and FP could not be retrieved. Therefore, diagnostic accuracy evaluation of symptom screening was not possible. Second, our analysis did not include the diagnostic accuracy of other COVID-19 diagnostic tests, such as antigen tests, as our search found no articles on other screening tests in asymptomatic preoperative patients. However, recent studies on the diagnostic accuracy of antigen tests show varying sensitivity rates for detecting COVID-19 in asymptomatic RT-PCR positive patients, and a previous study displayed no clinical role for serological testing in asymptomatic patients. Third, the current study did not address possible factors, for example, age, sex, type of surgical procedure, length of hospital stay, period of testing or comorbidities, and different estimates affecting the asymptomatic prevalence of COVID-19 in patients undergoing surgical procedures. However, these factors can most likely be pooled into a meta-analysis once cohorts and/or registries studies are published. In addition, to our knowledge, no research articles have been published to date including these tests in our patient group. Therefore, further research is warranted to explore the possible advantage of these tests. Finally, this meta-analysis was not able to evaluate the possible consequences of (unnecessary) delayed surgical procedures. Further research on surgical outcomes during the COVID-19 pandemic may provide additional information for optimising the surgical approach during a future pandemic.

In conclusion, the pooled prevalence of COVID-19 in asymptomatic preoperative patients was low (0.76%). Since nearly 60% of postponed surgical procedures in asymptomatic preoperative patients may be FP, surgical procedures may be unnecessarily delayed. In the event of similar pandemics, modification of preoperative mandatory RT-PCR COVID-19 testing in asymptomatic patients may be considered.

Contributors EdB: conception and design, data collection, analysis and interpretation, writing the article, critical revision of the article. MDF: conception...
REFERENCES
1 World Health Organization. WHO coronavirus (COVID-19) dashboard [online]. Available: https://covid19.who.int [Accessed 12 Apr 2021].
2 Al-Jabir A, Kerwan A, Nicola M, et al. Impact of the Coronavirus (COVID-19) pandemic on surgical practice - part 1. Int J Surg 2020;79:168–79.
3 Al-Jabir A, Kerwan A, Nicola M, et al. Impact of the Coronavirus (COVID-19) pandemic on surgical practice - part 2 [surgical prioritisation]. Int J Surg 2020;79:233–48.
4 NVVH. Handle for surgical procedures during corona crisis [online]. 2020. Available: https://heeikunde.nl/nieuws/nieuwsbericht?newsidm=23568500 [Accessed 16 May 2022].
5 Dutch Broadcasting Foundation. Healthcare authority: dozens of hospitals cancelled urgent operations because of corona [online]. 2020. Available: https://heeikunde.nl/nieuws/nieuwsbericht?newsidm=23454745 [Accessed 12 Apr 2021].
6 Volkskrant. Hospitals are forced to postpone heart and cancer operations due to overflowing ICs [online]. 2020. Available: https://www.volkskrant.nl/nieuws/achtergrond/ziekenhuizen-stellen-noodgevorderd-hart-en-kankeroperaties-u-door-volstronomende-ic-s-bca0b9339f [Accessed 12 Apr 2021].
7 Dutch Broadcasting Foundation. Non-urgent care will be scaled down, consultation hours and urgent care will continue as usual [online]. 2020. Available: https://nrs.nl/artikel/2362513-zorgautoriteit-tientallen-ziekenhuizen-schrappen-dirigende-operaties-door-corona.html [Accessed 12 Apr 2021].
8 Al-Murharraqi MA. Testing recommendation for COVID-19 (SARS-CoV-2) in patients planned for surgery - continuing the service and ‘suppressing’ the pandemic. Br J Oral Maxillofac Surg 2020;58:503–5.
9 Ribal MJ, Cornford P, Brigantti A, et al. European association of urology guidelines offer rapid reaction group: an organisation-wide collaborative effort to adapt the European association of urology guidelines recommendations to the coronavirus disease 2019 era. Eur Urol 2020;78:21–8.
10 Blouhos K, Boulas KA, Paraskova A, et al. Understanding surgical risk during COVID-19 pandemic: the rationale behind the decisions. Front Surg 2020;7:33.
11 Federation of Medical Specialists. Preoperative screening for SARS-CoV-2 infection in asymptomatic patients scheduled for surgery under general anesthesia [online]. 2021. Available: https://www.demedischspecialist.nl/sites/default/files/leidaad_preoperatieve_workup.pdf
12 Clinical manifestations of COVID-19 in the general population: a systematic review. Wien Klin Wochenschr 2020.
13 Alimohamadi Y, Sepandi M, Taghdir M, et al. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg 2020;61:E304–12.
14 Alene M, Yismaw L, Assenme MA, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: a systematic review and meta-analysis. PLoS One 2021;16:e0249090.
15 He J, Guo Y, Mao P, et al. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol 2021;93:820–30.
16 van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
17 Tran K, Cimon K, Severin M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012;7:e35797.
18 Kumar S, Kapoor L, Barman D, et al. Aerosol-mediated transmission of SARS-CoV-2 or COVID-19 in the cardiac surgical operating room. J Card Surg 2020;35:1755–7.
19 Patel MO, Chaisson LH, Borgetti S, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility. Clin Infect Dis 2020;71:1980–20.
20 Emery JC, Russell TW, Liu Y, et al. The contribution of asymptomatic SARS-CoV-2 infections to transmission on the diamond Princess cruise ship. Sci Transl Med 2020;12:eabc6780. doi:10.1126/scitranslmed.abf2753.
21 Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis 2020;96:288–90.
22 Van Vink Chau N, Lam VT, Dung NT, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis 2020;70:287–97.
23 Li C, JF, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-Family cluster, Xuzhou, China. Emerg Infect Dis 2020;26:1626–8.
24 Kurani N, Politiz K, Cotlar D. COVID-19 test prices and payment policy [online]. 2021. Available: https://healthsystemtracker.org/brief/covid-19-test-prices-and-payment-policy/ [Accessed 15 Sep 2021].
25 Fair Health. The projected economic impact of the COVID-19 pandemic on the US healthcare system [online]. 2020. Available: https://s3.amazonaws.com/media2.fairhealth.org/brief/asset/FairHealth. The projected economic impact of the COVID-19 pandemic on the US Healthcare System.pdf [Accessed 12 Apr 2021].
26 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
27 Prokop M, van Everdingen W, van Rees Vellinga T, et al. RSNA expert review and meta-analysis of studies that evaluated chest imaging in COVID-19 patients suspected of having COVID-19: a tool for selecting the most appropriate CT or chest X-ray imaging under general anesthesia. Clin Radiol 2020;75:196–200.
28 Byrne D, Neill Siobhan B O’, Müller NL, et al. RSNA expert consensus statement on reporting chest CT findings related to COVID-19: interobserver agreement between chest radiologists. Can Assoc Radiol J 2021;72:159–66.
29 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
30 Tenny S, Hoffman MR. Prevalence. StatPearls. 2021.
31 World Health Organization. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic [online]. Available: https://covid19.who.int/media-centre/fact-sheets/diagnostics-to-support-response-to-the-covid-19-pandemic
32 World Health Organization. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 [online]. Available: https://covid19.who.int/media-centre/factsheets/diagnostics-to-support-response-to-the-covid-19-pandemic
33 Byrne D, Neill Siobhan B O’, Müller NL, et al. RSNA expert consensus statement on reporting chest CT findings related to COVID-19: interobserver agreement between chest radiologists. Can Assoc Radiol J 2021;72:159–66.
34 U.S. Department of Health and Human Services. Coronavirus disease 2019 (COVID-19): recommendations for infection prevention and control in healthcare settings. 2020. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html
35 World Health Organization. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 [online]. Available: https://covid19.who.int/media-centre/fact-sheets/diagnostics-to-support-response-to-the-covid-19-pandemic
Properly COVID-19 testing for elective virenotretinal surgeries: experience from a major tertiary care institute in South India. Indian J Ophthalmol 2020;68:2373–7.

58. Neekanti SS, Vasudev Nair S, Parmar V, et al. Mandatory preoperative COVID-19 testing for cancer patients - Is it justified? J Surg Oncol 2020;122:1288–92.

59. Ralhan S, Aanya RC, Gupta R, et al. Cardiothoracic surgery during COVID-19: our experience with different strategies. Ann Card Anaesth 2020;23:485–92.

60. Senger JS, Cheng EM, Murad DA, et al. Low prevalence (0.13%) of COVID-19 infection in asymptomatic pre-operative/pre-procedure patients at a large, academic medical center informs approaches to perioperative care. Surgery 2020;168:980–6.

61. Tilmans G, Chenevas-Paule Q, Muller X, et al. Surgical outcomes after systematic preoperative testing and molecular screening for respiratory syndrome coronavirus 2 (SARS-CoV-2) screening. Surgery 2020;168:209–11.

62. Urban MJ, Patel TR, Raad R, et al. Implementation of preoperative screening protocols in otolaryngology during the COVID-19 pandemic. Otolaryngol Head Neck Surg 2020;163:265–70.

63. Zahra W, Dixon JW, Mirtorabi N, et al. Safety evaluation of a strategy to restart elective orthopaedic surgery during the de-escalation phase of the COVID-19 pandemic. Bone Jt Open 2020;1:450–6.

64. Wattsworth NJ, Myles PS, Mann GJ, et al. Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study. ANZ J Surg 2021;91:27–32.

65. Garjain J, Haroun F, Voicu A, et al. Cancer surgery during the COVID-19 pandemic: the experience of a comprehensive cancer center performing preoperative screening by RT-PCR and chest CT scan. J Surg Oncol 2021;123:815–22.

66. Hendrickson NR, Kesler K, DeMik DE, et al. Asymptomatic pre-operative COVID-19 screening for essential and elective surgeries: early results of a clinical study. Surgery 2021;169:27–38.

67. Lopes A, Pastore CBP, Deckers P. Ophthalmic surgery during the COVID-19 pandemic: effectiveness of preoperative screening and factors associated with postoperative SARS-CoV-2 infection. Ann Surg Oncol 2022.

68. Myles PS, Wallace S, Story DA, et al. COVID-19 risk in elective surgery during a second wave: a prospective cohort study. ANZ J Surg 2021;91:22–6.

69. Patkar S, Voppuru SR, Thiagarajan S, et al. Incidence of SARS-CoV-2 infection among asymptomatic patients undergoing preoperative COVID testing prior to cancer surgery: ASPET study. J Surg Oncol 2022;125:564–9.

70. Singh M, Sethi HS, Gupta S, et al. Preoperative covid-19 testing for elective ophthalmological procedures in a tertiary health care centre: our experience during the pandemic. Clin Ophthalmol 2021;15:3841–5.

71. Cwalinski J, Cwalinska A, Paszkowski J, et al. The role of diagnostic management in COVID-19 screening of asymptomatic patients admitted for elective surgery. in vivo 2021;35:3321–3.

72. Zangrilli J, Hameed D, Chisari E, et al. Mandatory preoperative COVID-19 testing for cancer patients-is it justified? J Surg Oncol 2020;122:1288–92.

73. de Winter L, van der Plas WV, Voicu A, et al. Preoperative COVID-19 screening for essential and elective surgeries: early results of a clinical study. Surgery 2021;169:27–38.

74. Cavanagh FG, Brinkman D, James DL, et al. Outcomes of preoperative real-time polymerase chain reaction testing for SARS-CoV-2 infection in elective otolaryngology surgical patients during the pandemic: a prospective cohort study. Br J Surg 2021;108:452. doi: 10.1053/j.bjsa.2020.06.028

75. Jonker PKC, van der Plas WV, Steinkamp PJ, et al. Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: a Dutch, multicenter, matched-cohort clinical study. J Cardiothorac Vasc Anesth 2021;35:1315–20.

76. Moghadam SM, Fitzpatrick MC, Sah P, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A 2020;117:17513–5.

77. Byambasuren O, Cardona M, Bell K. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Off J Assoc Med Microbiol Infect Dis Canada 2020;5:223–34.

78. Schulvins PM, Bulis M, Boonman-de Winter L, et al. Impact of the COVID-19 lockdown strategy on vascular surgery practice: more major amputations than usual. Ann Vasc Surg 2020;69:74–9.

79. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2021;3:CD013705.

80. Pray IW, Ford L, Cole D, et al. Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep 2021;69:1642–7.

81. Turcato G, Zaboli A, Pfeifer N, et al. Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report. J Infect 2021;82:e11–16.

82. Winkels BMF, Schram E, Gremmels H. Screening for SARS-CoV-2 infection in asymptomatic individuals using the PanbioTM COVID-19 antigen rapid test (Abbott) compared to RT-qPCR. medRxiv Prepr Serv Heal Sci 2020.

83. Arpino G, De Angelis C, De Placido P, et al. Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. ESMO Open 2020;5:e000885.